CDK4 and hypersensitivity reaction disease: Further, based on clinicaltrials.gov, the INAVO123 study is planned to evaluate inavolisib combined with letrozole and a CDK4/6 inhibitor in endocrine-sensitive breast cancer (NCT06790693).